Investor Call during the 17th International Conference of SCWD
You can find the video of the Obesity Investor Call and the presentation of the various speakers by clicking on this link:
Webcast of 17 January 2024 on our ambitions with Ruvembri® in respiratory viral infections
Following the recent publication of the results of the COVA clinical trial (phase 2-3) in eClinicalMedicine (The Lancet), Biophytis organized a webcast to present the Group’s ambitions in the treatment of respiratory viral infections such as Covid-19 and influenza. https://vimeo.com/905775870
Exclusive interview with Biotech Info, Stanislas Veillet unveils the capital increase for Sarconeos (BIO101)
In an exclusive interview with Biotech Info (in French), Stanislas Veillet, CEO & co-founder of Biophytis, unveils the capital increase for Sarconeos (BIO101) targeting severe COVID-19 & sarcopenia. With Phase 3 trials in sight, shareholders are invited to join this pivotal phase. Read here
SEPTEMBER 12, 2023
During the 25th annual H.C. Wainwright Global Investment Conference, Biophytis’ CEO Stanislas Veillet presented the company, its ambitions and the latest progress it made on its various projets. A replay will be available for 90 days at the following link: https://journey.ct.events/view/1037e68b-3f79-4b25-9a15-27affba4d7c4 Watch here
Interview with Stanislas Veillet on September 11, 2023 on Investisseur TV (In French)
Biophytis : nouvelles positives en matière d’autorisations et de financement
JANUARY 17, 2022
Decoding #BIOTECH on Maddyness Read in French “Covid-19 : ces BioTech françaises engagées dans la course aux traitements” Read article in French on www.maddyness.com
OCTOBER 06, 2021
Biophytis hosted a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and Sarcopenia